Analysis of antithrombotic therapy in elderly patients with atrial fibrillation

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Atrial fibrillation (AF) is a common condition in elderly patients.
• Antithrombotic therapy is crucial for preventing thromboembolic events in AF.
• Elderly populations present unique challenges in managing antithrombotic treatment due to comorbidities and altered pharmacokinetics.

Purpose of the Study:

• To analyze the impact factors and outcomes of antithrombotic therapy in elderly patients (over 65 years) with AF.
• To evaluate the patterns of antiplatelet and anticoagulation use across different age subgroups in the elderly AF population.
• To identify the incidence of thromboembolic events and bleeding complications associated with antithrombotic therapy in this demographic.

Main Methods:

• Retrospective analysis of clinical characteristics and antithrombotic therapy in 256 elderly patients with AF.
• Patients were stratified into three age groups: 65-74, 75-84, and over 85 years.
• Data on antithrombotic treatments, thromboembolic events (deep vein thrombosis, atrial thrombosis), and bleeding events (gastrointestinal hemorrhage, brain hemorrhage) were collected and analyzed.

Main Results:

• 187 out of 256 elderly patients received antithrombotic therapy.
• Antiplatelet therapy was more common than anticoagulation across all age groups, particularly in the 65-74 year-old group (90.7%).
• Incidence of thromboembolic events (5.9%) and bleeding complications (2.7% for GI hemorrhage, 21.7% for brain hemorrhage with anticoagulation) were observed.

Conclusions:

• Suboptimal antithrombotic therapy was identified in elderly patients with AF.
• The study highlights the delicate balance between preventing thromboembolism and managing bleeding risks in older adults with AF.
• Further research is needed to optimize antithrombotic strategies for the elderly AF population, considering age-specific factors and risk profiles.